Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKF‑81,297 is a potent and selective small molecule agonist of dopamine D1-like receptors (primarily D1 and D5 subtypes). It is widely used in research to study dopaminergic neurotransmission and behavior. The compound has high affinity for the dopamine D1 receptor (Ki ≈ 2 nM) and stimulates motor activity in animal models of Parkinson’s disease. In addition to its primary action as a D1 receptor agonist—mediating excitatory neurotransmission—it has been shown to modulate NMDA receptor currents independently of D1 activation at certain concentrations. This off-target effect may have implications for interpreting experimental results using this compound[1][3][4][7]. SKF‑81,297 is not approved for clinical use; it is used exclusively as a research tool.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SKF-81,297.